with modified Mallampati Class I and II airway, undergoing elective surgery requiring general anesthetic and orotracheal intubation were enrolled.
The patients were randomly allocated (computer-generated randomization table) into three groups of 30 patients (Group A, Group B, and Group C). The exclusion criteria included patients at risk for gastric aspiration, anticipated difficult airway and pregnancy. Patients taking drugs that interfere with neuromuscular function and with electrolyte imbalance/respiratory/neuromuscular disorders were also excluded from this study.
The total dose of atracurium used in all patients was 0.5 mg/kg body weight, including the priming dose. Each group received different priming doses of atracurium as follows: Group A received 0.05 mg/kg body weight, Group B received 0.025 mg/kg body weight, whereas Group C (control) received saline as priming dose.
There were three observers in the study. Observer 1 was the postgraduate in anesthesiology blinded to group allocation, who evaluated the patients preoperatively on the day before surgery and selected patients who met the inclusion criteria, observed and recorded the study parameters. Observer 2 was the consultant anesthesiologist nonblinded to the group allocation who was involved with the preparation of priming dose and intubating dose of study drug and carried out intravenous induction of anesthetic. Observer 3 was an additional consultant nonblinded to group allocation, who carried out preoxygenation, bag-mask ventilation, and intubation.
Preoperative evaluation of the patients was done on the day before surgery and written informed consent obtained. All patients were kept nil per orally for minimum of 2 h for clear liquids and 6 h for solid food and premedicated with tablet pantoprazole 40 mg and metoclopramide 10 mg on the morning of day of surgery. Inside the operating room, intravenous access was established and all the patients were monitored with pulse oximetry, noninvasive blood pressure, and 5-lead electrocardiography. A peripheral nerve stimulator (Fisher and Paykel healthcare Ltd, Auckland, New Zealand) capable of delivering TOF stimulus was attached to the dominant hand of the patient to visually monitor thumb adduction by stimulating ulnar nerve at wrist. Observer 2 loaded the atracurium priming dose as well as intubating dose as per the group allocation and body weight of patients. The atracurium besylate (Artacil, Neon laboratories Ltd, vial containing 25 mg/2.5 ml) was diluted in a 10 ml syringe so as to yield 5 mg/ml. If the patient weighed >50 kg, two ampoules of atracurium were taken. For finer dilution of drug insulin syringe was used to yield an accuracy up to 25 µg, which was required for the study. Observer 3 preoxygenated the patients using 100% oxygen through a tight-fitting facemask for 3 min followed by intravenous administration of priming dose by observer 2. In patients belonging to Group C (control group), 10 ml of normal saline was used for priming. Oxygen administration continued for the next 3 min, during which adverse effects related to priming such as diplopia, ptosis (the distance between pupillary center and upper eyelid margin when the patient looks straight ahead), shortness of breath, motor weakness, and desaturation were observed and recorded by Observer 1 at the end of each minute. In the event of desaturation <92% any time within 3 min after priming, the patient was provided intravenous induction of the anesthetic and the case excluded from further statistical analysis.
After the completion of 3 min after priming, intravenous induction of the anesthetic was done by Observer 2 using propofol 2 mg/kg, fentanyl 2 µg/kg, and intubating dose of atracurium was administered. This was 0.45 mg/kg in Group A, 0.475 mg/kg in Group B, and 0.5 mg/kg in Group C, respectively, thus ensuring that the total dose of atracurium used was 0.5 mg/kg body weight. After completion of administration of intubating dose of atracurium, Observer 1 switched on the peripheral nerve stimulator (placed to stimulate ulnar nerve of dominant hand at wrist using 40 mA current strength) to monitor the TOF count by visual means of thumb adduction and also started the timer to record the time (t) from the administration of intubating dose of atracurium till TOF count reached zero. Once the patient went apneic, Observer 3 performed bag-mask ventilation with 100% oxygen and isoflurane to achieve a minimum alveolar concentration of 1-1.3. After TOF count reached zero, intubation was carried out and surgical procedure begun. Observer 1 was blinded to the group allocation of patients till the completion of the study. It was disclosed once the data were collected and were due for statistical analysis.
Statistical analysis
For the present study to have a power of 80%, confidence interval of 95%, acceptable Type I error of 5%, a time of 20 s to be of significance, the sample size required was 30 in each group. All the 90 patients completed the study, with nil dropouts. SPSS version 16.0 (Chicago, SPSS Inc) was used for statistical analysis. Chi-square test and ANOVA were used to analyze the data.
reSultS
Patients were comparable with respect to demographic data [ Table 1 ]. ANOVA test was used to compare the mean age, height, weight, and body mass index between groups (with P values being 0.648, 0.063, 0.072, and 0.16, respectively), which revealed no statistical significance. The mean time to achieve a TOF of zero was tested with ANOVA test and statistically significant difference among three groups [ Table 2 ]. A post hoc test (Tukey) was done to compare two groups at a time, which revealed that statistically significant differences in time existed between groups [ Table 3 ]. Of 60 patients who were administered atracurium as priming drug, two patients in Group A had ptosis at the end of 3 min after priming with 0.05 mg/kg body weight, with no other side effects [ Table 4 ].
dIScuSSIon
The introduction of neuromuscular blockers revolutionized the anesthetic practice, which thereafter underwent a conceptual change. Muscle relaxants are classified into two groups, the depolarizers and nondepolarisers. Suxamethonium is the only depolarizer in use which causes profound muscle relaxation within 60 s after intravenous administration. Important nondepolarisers in clinical use in our country are vecuronium, atracurium, cisatracurium, and rocuronium. They cause competitive blockade of neuromuscular junction. Most of the nondepolarisers have slower onset of action and are not suitable for rapid control of airway. In 1956, Stenlake et al. synthesized atracurium. Atracurium and its isomers are different from other nondepolarisers because of their organ independent elimination. Atracurium is eliminated predominantly by two pathways: Ester hydrolysis and Hofmann elimination. [6, 7] Suxamethonium remains the drug of choice when rapid tracheal intubation is needed. However, there are certain clinical situations wherein suxamethonium is contraindicated. [8] Hence, efforts were made to hasten the onset of action of nondepolarisers. These include priming technique, or the use of high doses of an individual agent or by a combination of different neuromuscular blockers. [5] With higher dose of atracurium (0.6 mg/kg), onset of action is faster and produced improved conditions for intubation. Higher doses also caused more adverse reactions such as cutaneous flushing, hypotension, and bronchospasm due to histamine release. [9] The priming principle was introduced in 1980s to decrease the time of onset of action of NDMR. With the use of rocuronium this method is somewhat forgotten, although still used. In this method a small, subparalyzing dose of the nondepolarizing agent (20% of the ED 95 or 10% of the intubating dose) is administered to the patient 2-4 min before the intubating dose of the drug. The mechanism is that when priming dose is administered, it will accelerate the onset of neuromuscular blockade by 30-60 s, thereby facilitating intubation quickly within 90 s after the intubating dose. [5] Priming dose results in 70%-75% of cholinergic receptor occupancy and subsequent dose administered after the priming dose leads to >90% receptor occupancy, which is required for profound muscle relaxation. In reality, intubating conditions after priming do not match those after suxamethonium. Some adverse effects were also encountered while priming had been employed and these are patient discomfort, aspiration risks, difficulty in swallowing/coughing and diplopia. [5, 10] This technique is not applicable for those with difficult airway and increased sensitivity to neuromuscular blocking drugs such as myasthenia gravis or those who are taking drugs known to interfere with neuromuscular function.
In 1986, Naguib et al. conducted a study to find out the optimal priming dose of atracurium using wider range of priming dose of atracurium (from 0.04 mg/kg to 0.09 mg/kg) with a priming interval of 3 min. In this study, priming doses in the range of 0.04-0.09 mg/kg were associated with statistically significant reduction in the TOF ratios, which facilitated rapid tracheal intubation. The optimal priming dose of atracurium was 0.05 mg/kg, which had lesser incidence of adverse effects related to priming. They concluded that optimal priming dose of atracurium was 0.05 mg/kg, which has lesser incidence of adverse effects related to priming. [11] In our study, we used two different priming doses of 0.05 and 0.025 mg/kg body weight 3 min before intubating dose, which had further helped to reduce the incidence of adverse effects. In our study, time after intubating dose required for TOF count to reach zero was far higher than ideal time of <90 s required for rapid sequence intubation. Another study conducted by Naguib et al. regarding rapid tracheal intubation with atracurium and comparing the priming intervals concluded that when priming dose of atracurium is given 3 min before the intubating dose, it can prove as an alternative to succinylcholine for rapid endotracheal intubation. [12] In our study, we have used a priming interval of 3 min, which is optimal as found out by several other studies. In a study conducted by Mishra et al. on the effect of priming on intubating conditions produced by atracurium, they found that atracurium in a total dose of 0.7 mg/kg utilizing priming principle provided excellent intubating conditions at 120 s after intubating dose. Priming dose of 0.1 mg/kg (i.e., approximately 14.3% of total dose) appeared satisfactory without any side effects. [13] Similarly, the priming principle study done by Jaradi et al. regarding shortening the onset time of atracurium for rapid tracheal intubation concluded that priming dose of 0.07 mg/kg given 3 min before induction shortens the atracurium onset time to 60 s. However, out of 60 patients, 13 patients had ptosis as adverse effect. [14] In our study of 60 patients who were administered atracurium as priming drug, we encountered two cases of ptosis at the end of 3 min after priming with 0.05 mg/kg body weight, with no other side effects. This may have occurred possibly owing to wider inter-individual variations in response to nondepolarizing neuromuscular blockers.
This study has a few limitations. The intubating conditions when priming had been employed were not studied. Laryngeal musculature is known to have different sensitivity to muscle relaxants than the muscles supplied by ulnar nerve. Results with priming dose >0.05 mg/kg body weight was not studied owing to the potential for significant muscle weakness, which may be highly distressing for awake patients. The results obtained with atracurium cannot be extrapolated to other NDMR.
concluSIonS
Priming principle employing atracurium reduces the time required for TOF count to reach zero by approximately 71 s while using 0.05 mg/kg body weight and by around 25 s while employing 0.025 mg/kg body weight, with clinically insignificant incidence of adverse effects.
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